Soligenix is a small biotech company that will announce results from two separate PH 3 clinical trials: FLASH study SGX301 in patients with cutaneous T cell lymphoma (CTCL) will be announced in 2 months, and top-line results of DOM-INNATE study of SGX942 for the treatment of oral mucositis in patients with concomitant chemoradiotherapy for Head and Neck cancer are expected 4 months after that.
Cutaneous T cell lymphoma (CTCL) is a rare type of lymphoma and there is no FDA approved therapy for the early stage of the disease. It is estimated that around 20